氯吡格雷抵抗基因多态性的研究进展  

Review on Clopidogrel Resistant Genetic Polymorphisms

作　　者：张晶[1] 马依彤[1] 穆巴拉克[2] 

机构地区：[1]新疆医科大学第一附属医院心脏中心,新疆乌鲁木齐830002 [2]新疆医科大学药学院,新疆乌鲁木齐830054

出　　处：《心血管病学进展》2012年第1期51-54,共4页Advances in Cardiovascular Diseases

摘　　要：氯吡格雷是目前广泛应用的抗血小板药物,其对血小板的抑制具有个体差异性,部分患者在服用常规剂量氯吡格雷后存在抵抗现象而发生临床血栓事件。目前氯吡格雷抵抗的机制尚不十分清楚,基因多态性被认为是其中一个重要的原因。现就氯吡格雷抵抗基因多态性作一综述。Clopidogrel is a widely used antiplatelet aggregation drug. However, clopidogrel-induced platelet inhibition is patient-spe- cific. The presence of clopidogrel resistance indicates that cardiovascular events can still occur in patients taking standard dose clopidogrel therapy. At present the clopidogrel resistance mechanism still is not very clear, genetic polymorphism is considered to be one of the important reasons. This article discusses currently available evidence surrounding the genetic polymorphisms of clopidogrel resistance.

关 键 词：氯吡格雷抵抗 基因多态性 

分 类 号：R541.4[医药卫生—心血管疾病]